Company Overview:
Celcuity is a commercial-stage biotechnology company focused on developing targeted therapies for multiple solid tumour indications. The company's first FDA-approved product is REVTORPYK for breast cancer.
Key Executives
Chief Executive Officer: Brian Sullivan
Chief Financial Officer: Vicky Hahne
Celcuity Inc. (CELC) announced that it has submitted a supplemental New Drug Application to the U.S. FDA seeking approval for REVTORPYK for patients with hormone receptor positive, HER2-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation, following at least one line of endocrine therapy.
Celcuity Inc. (CELC), a biotechnology company, announced that the U.S. Food and Drug Administration has approved REVTORPYK (gedatolisib) for the treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast...
Celcuity Inc. (CELC) recently reported new clinical and regulatory progress for Gedatolisib, its PI3K/mTOR inhibitor being evaluated across multiple late-stage programs for HR-positive, HER2-negative advanced breast cancer.
Celcuity Inc. (CELC), a clinical-stage biotechnology company, on Wednesday announced the pricing of its upsized underwritten public offering. The company is offering $500 million in an aggregate principal amount of convertible senior notes due 2032, increased from the previously announced $400 million...
Celcuity Inc. (CELC) stock fell 22.41 percent to $95.41, losing $27.55 on Tuesday, despite announcing detailed positive efficacy data from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 clinical trial for gedatolisib.
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.